FoxP3+ Tregs were strongly associated with reduced lower OS rate in ER+ breast cancer cases, with a pooled OR of 1.50 (95% CI 1.17 to 1.93), but was associated with a improved survival in ER- cases, with a pooled OR of 0.45 (95% CI 0.31 to 0.65). This evidence concerns the gene FOXP3 and breast carcinoma.